Akanda (AKAN) Competitors $1.38 -0.05 (-3.50%) Closing price 03:54 PM EasternExtended Trading$1.44 +0.06 (+4.28%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AKAN vs. PHIO, CHRO, GLTO, DWTX, AIMD, BGXX, ADXN, OBSV, BCLI, and ONCOShould you be buying Akanda stock or one of its competitors? The main competitors of Akanda include Phio Pharmaceuticals (PHIO), Chromocell Therapeutics (CHRO), Galecto (GLTO), Dogwood Therapeutics (DWTX), Ainos (AIMD), Bright Green (BGXX), Addex Therapeutics (ADXN), ObsEva (OBSV), Brainstorm Cell Therapeutics (BCLI), and Onconetix (ONCO). These companies are all part of the "pharmaceutical products" industry. Akanda vs. Phio Pharmaceuticals Chromocell Therapeutics Galecto Dogwood Therapeutics Ainos Bright Green Addex Therapeutics ObsEva Brainstorm Cell Therapeutics Onconetix Phio Pharmaceuticals (NASDAQ:PHIO) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership. Does the MarketBeat Community favor PHIO or AKAN? Phio Pharmaceuticals received 37 more outperform votes than Akanda when rated by MarketBeat users. CompanyUnderperformOutperformPhio PharmaceuticalsOutperform Votes3763.79% Underperform Votes2136.21% AkandaN/AN/A Does the media favor PHIO or AKAN? In the previous week, Phio Pharmaceuticals and Phio Pharmaceuticals both had 1 articles in the media. Phio Pharmaceuticals' average media sentiment score of 1.87 equaled Akanda'saverage media sentiment score. Company Overall Sentiment Phio Pharmaceuticals Very Positive Akanda Very Positive Which has higher earnings and valuation, PHIO or AKAN? Phio Pharmaceuticals has higher earnings, but lower revenue than Akanda. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhio PharmaceuticalsN/AN/A-$10.83M-$10.92-0.12Akanda$2.51M0.79-$32.28MN/AN/A Do analysts recommend PHIO or AKAN? Phio Pharmaceuticals currently has a consensus target price of $4.00, indicating a potential upside of 207.69%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Phio Pharmaceuticals is more favorable than Akanda.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Akanda 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals have more ownership in PHIO or AKAN? 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.0% of Akanda shares are owned by institutional investors. 0.6% of Phio Pharmaceuticals shares are owned by company insiders. Comparatively, 20.4% of Akanda shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, PHIO or AKAN? Phio Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, Akanda has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Is PHIO or AKAN more profitable? Akanda's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Phio PharmaceuticalsN/A -134.57% -108.39% Akanda N/A N/A N/A SummaryPhio Pharmaceuticals beats Akanda on 6 of the 11 factors compared between the two stocks. Remove Ads Get Akanda News Delivered to You Automatically Sign up to receive the latest news and ratings for AKAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKAN vs. The Competition Export to ExcelMetricAkandaMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.97M$1.14B$5.64B$7.80BDividend YieldN/AN/A5.34%4.03%P/E RatioN/A9.3123.6318.68Price / Sales0.795.66370.1089.74Price / CashN/A10.4038.1734.64Price / Book-0.021.176.744.12Net Income-$32.28M-$54.34M$3.20B$247.10M7 Day Performance-12.10%-6.28%-5.62%-3.82%1 Month Performance-17.86%-16.56%-0.37%-6.24%1 Year Performance-85.21%-41.14%7.73%-1.89% Akanda Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKANAkandaN/A$1.38-3.5%N/A-84.7%$1.97M$2.51M0.00110Positive NewsPHIOPhio Pharmaceuticals2.9012 of 5 stars$1.30+0.8%$4.00+207.7%-78.9%$8.95MN/A-0.1210Upcoming EarningsNews CoverageGap UpCHROChromocell TherapeuticsN/A$1.48-5.7%N/A-39.3%$8.92MN/A0.004Gap DownGLTOGalecto3.0144 of 5 stars$6.70+9.8%$10.00+49.3%-82.5%$8.82MN/A-0.3540Short Interest ↑High Trading VolumeDWTXDogwood TherapeuticsN/A$6.47+2.2%N/AN/A$8.62MN/A-0.995Earnings ReportGap UpAIMDAinos0.4759 of 5 stars$0.54+1.7%N/A-55.2%$8.32M$20,729.00-0.3340Short Interest ↑BGXXBright GreenN/A$0.04+16.2%N/A-75.4%$8.22MN/A-0.722ADXNAddex Therapeutics2.846 of 5 stars$7.69+0.3%$30.00+290.4%-39.0%$8.05M$556,045.00-22.6030Upcoming EarningsShort Interest ↓Gap UpOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst ForecastNews CoverageBCLIBrainstorm Cell Therapeutics3.8359 of 5 stars$1.37-2.8%$30.00+2,089.8%-86.0%$7.81MN/A-0.2940Upcoming EarningsNews CoverageONCOOnconetix0.5735 of 5 stars$0.12-6.4%N/A-98.5%$7.73M$1.87M0.0012High Trading Volume Remove Ads Related Companies and Tools Related Companies PHIO Competitors CHRO Competitors GLTO Competitors DWTX Competitors AIMD Competitors BGXX Competitors ADXN Competitors OBSV Competitors BCLI Competitors ONCO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKAN) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akanda Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akanda With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
